Alcohol and Drug Abuse

Transparency and integrity in scientific review and recommendations for future Dietary Guidelines for Americans Issues related to regulation of hemp products

Fighting to get Kratom declared a schedule 1 drug

Opioids, pain management Federal funding for substance use disorder treatments H.R.2004-Tylers Law, to direct the Secretary of Health and Human Services to issue guidance on whether hospital emergency departments should implement routine fentanyl testing for patients experiencing an overdose H.R. 2483-Support for Patients and Communities Reauthorization Act, to reauthorize grants and programs to address opioid and substance use disorder S.921-Tylers Law, to direct the Secretary of Health and Human Services to issue guidance on whether hospital emergency departments should implement routine fentanyl testing for patients experiencing an overdose S. 2121-Support for Patients and Communities Reauthorization Act, to reauthorize grants and programs to address opioid and substance use disorder S. 3522-No Red Tape for Addiction Treatment Act, to require that State Medicaid programs provide at least one formulation of each type of medication for the treatment of opioid use disorder without prior authorization or limitations on dosage

Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations. Related potential legislation (discussions particularly with Rep. Cline, Auchincloss, and Harder).

**Issues lobbied without specific bill number: Marijuana Research

Mental Health Substance use disorder H.R. 1, One Big Beautiful Bill Act; specifically, lobbying to amend Medicaid community engagement requirements to require states to perform ex parte verifications for individuals eligible for exceptions due to having a substance use disorder; lobbying House Energy and Commerce (majority and minority) and Senate HELP (majority and minority) on legislative language related to ex-parte verifications and 42 CFR Part 2 that would improve implementation of H.R. 1

Advocacy on the harms of drug use and drug criminalization through policy solutions, organizing, and public education.

Responsible drinking initiatives. Issues related to sale of distilled spirits. 2025-2030 Dietary Guidelines for America

Issues related to federal prisons, medically assisted treatment, opioid and substance use disorder, healthcare, telehealth, criminal justice, Medicaid and Medicare

Horseracing Integrity & Safety Act. OBBBA.